Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.

ABSTRACT:

Objectives

Overcoming racial differences in acute coronary syndrome (ACS) outcomes is a strategic goal for U.S. health care. Genetic polymorphisms in the adrenergic pathway seem to explain some outcome differences by race in other cardiovascular diseases treated with β-adrenergic receptor blockade (BB). Whether these genetic variants are associated with survival among ACS patients treated with BB, and if this differs by race, is unknown.

Background

β-adrenergic receptor blockade after ACS is a measure of quality care, but the effectiveness across racial groups is less clear.

Methods

A prospective cohort of 2,673 ACS patients (2,072 Caucasian; 601 African-American) discharged on BB from 22 U.S. hospitals were followed for 2 years. Subjects were genotyped for polymorphi

SUBMITTER: Cresci S 

PROVIDER: S-EPMC3678950 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature